| Previous close | 0.85 |
| Open | 0.85 |
| Bid | 0.80 x 0 |
| Ask | 0.90 x 0 |
| Day's range | 0.87 - 0.96 |
| 52-week range | 0.61 - 1.73 |
| Volume | 3,154,521 |
| Avg. volume | 5,514,579 |
| Market cap | 22.48M |
| Beta | N/A |
| PE ratio (TTM) | -∞ |
| EPS (TTM) | -0 |
| Earnings date | 31 Oct 2017 - 6 Nov 2017 |
| Dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.02 |
- Simply Wall St.•7 days ago
Can Sareum Holdings plc (AIM:SAR) Improve Your Portfolio Returns?
For Sareum Holdings plc’s (AIM:SAR) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. There are twoRead More...
- PR Newswire•last year
ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) From CRT Pioneer Fund, UK
PNT737 is being investigated in two recently initiated Phase 1 clinical trials, currently sponsored and managed by the Cancer Research UK Centre for Drug Development, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust.
We're sorry, but this is all we were able to find on this topic.
